CLINICAL TRIALS PROFILE FOR CEFTRIAXONE

505(b)(2) Clinical Trials for Ceftriaxone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00244777 ↗	Introduction of Hypo-osmolar ORS for Routine Use	Completed	United States Agency for International Development (USAID)	Phase 4	2002-12-01	The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.
New Formulation	NCT00244777 ↗	Introduction of Hypo-osmolar ORS for Routine Use	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 4	2002-12-01	The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.

All Clinical Trials for Ceftriaxone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	Hoffmann-La Roche	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000938 ↗	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) persistent infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of coinfection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, in seronegative patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).
NCT00001101 ↗	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) active infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of co-infection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, for seropositive patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).
NCT00002052 ↗	Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients	Completed	University of Southern California	N/A	1969-12-31	To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.
NCT00004216 ↗	VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy	Completed	Vion Pharmaceuticals	Phase 1	1999-08-01	RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous therapy.

Clinical Trial Conditions for Ceftriaxone

Condition Name

Condition Name for Ceftriaxone
Intervention	Trials
Pneumonia	11
Sepsis	9
Gonorrhea	6
Surgical Site Infection	5

Condition MeSH

Condition MeSH for Ceftriaxone
Intervention	Trials
Infections	43
Pneumonia	35
Infection	34
Communicable Diseases	28

Clinical Trial Locations for Ceftriaxone

Trials by Country

Trials by Country for Ceftriaxone
Location	Trials
United States	245
France	35
Australia	32
Spain	26
Canada	26

Trials by US State

Trials by US State for Ceftriaxone
Location	Trials
Ohio	19
California	18
Texas	14
North Carolina	13
New York	13

Clinical Trial Progress for Ceftriaxone

Clinical Trial Phase

Clinical Trial Phase for Ceftriaxone
Clinical Trial Phase	Trials
PHASE4	8
PHASE3	4
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Ceftriaxone
Clinical Trial Phase	Trials
Completed	97
Recruiting	30
Unknown status	23

Clinical Trial Sponsors for Ceftriaxone

Sponsor Name

Sponsor Name for Ceftriaxone
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	11
Forest Laboratories	8
Assistance Publique - Hôpitaux de Paris	7

Sponsor Type

Sponsor Type for Ceftriaxone
Sponsor	Trials
Other	242
Industry	62
NIH	16

CEFTRIAXONE Clinical Trials Update, Market Analysis and Forecast (2024-2035)

Last updated: July 27, 2026

CEFTRIAXONE is an off-patent, widely genericized third-generation cephalosporin with mature global supply chains. Commercial growth is driven by hospital tender cycles, guideline-based use in acute bacterial infections, and episodic demand spikes from outbreaks and seasonal respiratory disease. Forecast upside depends less on new molecular efficacy and more on procurement economics, resistance trends, and stewardship constraints that shift mix toward broader-spectrum comparators in some indications.

How is ceftriaxone performing in the market and what is the forecast through 2035?

Answer: Market trajectory is steady-to-moderate growth globally with margin pressure from generics, and slower gains in markets where stewardship and guideline shifts reduce reliance for select indications. Growth is strongest in LMIC procurement due to low cost and broad-spectrum positioning.

Global demand drivers for ceftriaxone

• Hospital-first usage: Ceftriaxone is primarily used in inpatient and emergency settings for severe community-acquired infections, sepsis pathways, and empiric therapy where IV/IM administration is required.
• Low acquisition cost vs newer agents: In many formulary structures, ceftriaxone remains a preferred comparator because it is cheaper than carbapenems, ceftaroline, ceftazidime-avibactam, and newer beta-lactam/beta-lactamase inhibitor combinations.
• Antimicrobial stewardship influences: Stewardship programs can reduce unnecessary broad-spectrum use, but they often still recommend ceftriaxone as a first-line empiric agent for susceptible presentations.
• Resistance pressure changes mix, not elimination: Rising resistance in certain geographies limits coverage for specific pathogens, shifting usage toward alternatives. That said, ceftriaxone remains widely used due to formulary inertia and existing standard protocols.

Market forecast structure (what to model)

For investment, licensing, or business planning, forecast ceftriaxone revenues by:

1. Geography (North America, EU5, UK, Japan, China, India, LatAm, MENA, SSA)
2. Segment (adult vs pediatrics, inpatient vs outpatient)
3. Form (IV vs IM; vial size mix)
4. Public procurement sensitivity (tender cycles, reference price changes)
5. Substitution risk from:
   • carbapenem escalation for ESBL risk
   • newer cephalosporins and BL/BLI classes in hospital pathways

Competitive landscape: branded vs generic and pricing pressure

• Branded incumbents in many regions have largely ceded share to multi-supplier generics.
• Pricing is tender-led and frequently compresses margins on mature listings.
• Supply security and regulatory compliance (sterility assurance, control of particulate matter, batch consistency) matter as much as cost.

What growth rates to use in planning

Because this topic is requested as “market analysis and projection,” use a base-case envelope:

• Global revenue growth: low single digits to mid single digits annually in most years
• Volumetric growth: often outpaces revenue due to price erosion from new generic entrants and tender resets

What is the current clinical trials landscape for ceftriaxone?

Answer: Ceftriaxone trials are dominated by comparative empiric regimens, dosing optimization, pediatric safety, pharmacokinetics, and infection-specific protocol studies rather than late-stage “new molecular entity” development. The practical pipeline is mostly re-positioning in clinical protocols and formulation/delivery system work.

Types of ongoing or recent ceftriaxone studies

• Dose and PK/PD refinement
  • altered dosing in obesity, pediatrics, and renal/hepatic impairment
  • high-dose strategies for selected difficult infections
• Switch therapy and stewardship strategies
  • IV-to-oral sequences using ceftriaxone as the initial step
  • duration optimization to reduce overtreatment
• Combination regimens
  • ceftriaxone paired with macrolides, doxycycline, or metronidazole depending on syndrome
  • comparison vs alternative empiric regimens in guideline-aligned pathways
• Special populations
  • neonatal and infant dosing/safety monitoring
  • pregnancy outcomes and pharmacovigilance registries
• Delivery and formulation studies
  • stability, reconstitution quality, and administration convenience improvements

Where trial activity clusters

• Infectious disease hotspots: sepsis/emergency empiric pathways, pneumonia variants, skin/soft tissue infection protocols, intra-abdominal infection regimens (often in combination), and meningitis or meningitis-adjacent studies where ceftriaxone is a standard reference.
• Geographies with high enrollment potential: regions with large inpatient caseloads and active academic networks.

Which ceftriaxone trials matter for market and product strategy?

Answer: Trials that influence formularies and treatment guidelines are the ones that move demand. Studies that establish preferred dosing, reduce failure rates in resistant settings, or improve administration workflow can change tender mix even without patent protection.

Featured decision-impact endpoints

• Clinical cure and microbiological eradication
• Time to clinical stability
• Mortality endpoints in severe sepsis or meningitis pathways
• Treatment failure and relapse
• Adverse event rates (especially hypersensitivity and biliary sludging concerns, plus diarrhea rates linked to broad-spectrum use)

Trial-to-procurement translation channels

• Guideline committee adoption
• hospital sepsis protocol updates
• pediatric dosing label harmonization and institutional policy updates
• antimicrobial stewardship protocol incorporation

How do dosing, formulations, and administration route affect ceftriaxone adoption?

Answer: Route convenience (IM feasibility), reconstitution handling, pediatric suitability, and dosing protocols drive real-world use more than marginal efficacy changes.

IV vs IM: what shifts procurement

• IV dominates in intensive and emergency settings.
• IM supports outpatient referral pathways and resource-limited settings where IV access is constrained.

Pediatric considerations

• Ceftriaxone is widely used in pediatrics, but dosing schedules and safety monitoring for neonates remain a key determinant of adoption consistency across regions.

Packaging and logistics

• Vial size, shelf life, stability in transport, and reconstitution ease can affect procurement selection in tenders even when API cost is similar.

What is the IP and exclusivity situation for ceftriaxone in major markets?

Answer: Ceftriaxone is off-patent in most jurisdictions; the market is structurally generic, with IP emphasis shifting to:

• process patents for manufacturing
• formulation and stability work (where applicable)
• regulatory exclusivities tied to specific submissions rather than the molecule itself

Why patent strategy rarely drives ceftriaxone innovation

• Generic competition is entrenched.
• Clinical demand is governed by guideline and cost-effectiveness rather than patent-protected incremental benefits.

Business implication

New market entry is mostly a regulatory and manufacturing execution game, not a breakthrough-IP game.

What generic entry risks exist for ceftriaxone?

Answer: Entry risk is low on molecular IP but high on execution risk:

• regulatory approval delays
• batch release stability and sterility compliance
• inspection readiness (sterile manufacturing controls, environmental monitoring, particulates)

Typical barriers that still impact timelines

• Chemistry, manufacturing, and controls (CMC) documentation quality
• scale-up reproducibility for sterile API-derived drug substance
• container closure integrity and reconstitution performance validation

How does ceftriaxone compare with other cephalosporins and BL/BLI in clinical practice?

Answer: Ceftriaxone remains a go-to empiric cephalosporin where coverage is adequate, but alternative agents are preferred where resistance risk is high or where broader beta-lactamase inhibitor coverage changes outcomes in local antibiograms.

Substitution pressure points

• ESBL prevalence: can shift clinicians toward carbapenems or BL/BLI combinations depending on syndrome and institutional protocols.
• Hospital antibiograms: local resistance profiles drive empiric regimen choice.
• Toxicity and tolerability: diarrhea and hypersensitivity risk comparisons are considered in antibiotic stewardship decisions.

Competitive set in hospital tenders

• Ceftazidime (including ceftazidime-avibactam depending on setting)
• Cefepime
• Piperacillin-tazobactam
• Carbapenems
• Newer cephalosporins and BL/BLI where formularies support them

What regulatory status and FDA/Orange Book dynamics matter for ceftriaxone?

Answer: In the US, ceftriaxone is widely available as an approved generic. Business-relevant regulatory signals are less about new exclusivities for the molecule and more about:

• ANDA approvals for specific strengths and presentations
• labeling alignment
• manufacturing site changes and supplements
• shortages, discontinuations, and recalls that affect tender supply continuity

How strong is ceftriaxone’s commercial moat (and where does it erode)?

Answer: The moat is supply reliability, regulatory compliance, and contracting reach, not patent life. Erosion comes from price compression and substitution toward alternatives in high-resistance environments.

Moat strengths

• clinician familiarity
• broad coverage for many syndromes
• deep procurement acceptance
• predictable manufacturing and QC paradigms

Moat erosion vectors

• repeated price resets
• pipeline of additional generic approvals for common presentations
• higher institutional preference for broader-spectrum combinations in certain ICUs

Key Takeaways

• Ceftriaxone remains a mature, off-patent hospital workhorse with demand anchored in empiric inpatient therapy and guideline-aligned protocols.
• Clinical development is mostly PK/PD, dosing optimization, regimen strategy, and safety-focused rather than new-to-market drug discovery.
• Market growth is likely modest and tender-driven, with revenue constrained by persistent generic price competition.
• Competitive pressure increases where local resistance drives escalation to carbapenems or BL/BLI regimens; where ceftriaxone remains guideline-supported, it stays entrenched.
• Business upside centers on supply reliability, regulatory execution, and alignment with protocol-driven demand rather than IP breakthroughs.

FAQs

1. Are there any ceftriaxone-specific shortages risk signals that affect revenue planning?
2. Which infection syndromes drive the largest share of ceftriaxone inpatient use globally?
3. How does ceftriaxone resistance in ESBL-producing organisms affect hospital empiric protocols?
4. What dosing changes in pediatrics or neonates most influence clinical outcomes and labeling?
5. Do formulation or packaging improvements materially change tender selection for ceftriaxone?

References

1. World Health Organization. WHO Model List of Essential Medicines.
2. FDA. Drug Shortages Database and related safety/recall communications.
3. FDA. Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations).
4. ClinicalTrials.gov. Search results for ceftriaxone (accessed 2026-07-28).